Law360, New York (May 02, 2011, 7:06 PM ET) -- A New Jersey federal judge on Monday signed off on a joint stipulation of dismissal of AstraZeneca Pharmaceuticals LP’s case alleging Biovail Corp. infringed its patents by seeking to launch a generic version of AstraZeneca’s popular treatment for bipolar disorder and schizophrenia, Seroquel XR.
AstraZeneca and Biovail on Friday asked for the case to be dismissed after Biovail made a regulatory filing pursuant to which it agreed not to commercially sell its purportedly generic drug until after the expiration of the two patents-in-suit.
Following the action’s...
AstraZeneca Ends Seroquel Case Against Biovail
To view the full article, take a free trial now.
